Showing 828 results
-
Media Release /Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression…
-
Media Release /Treatment with Cosentyx (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both enthesitis-related arthritis (ERA) and…
-
Media Release /Statistically significant and clinically important reductions in proteinuria were achieved for the primary endpoint for patients with C3G(1) Additionally, statistically significant reduction in C3…
-
Media Release /Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine…
-
Media Release /In KESTREL and KITE, BEOVU (brolucizumab-dbll) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in…
-
Media Release /Black women with breast cancer are approximately 40% more likely to die compared to white women with breast cancer in the U.S.[1] - and are also more likely to be diagnosed at a later stage with…
-
Media Release /ALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there…
-
Media Release /At least 75% of children six years and older achieved PASI 90 at Week 52 when treated with Cosentyx in two pivotal studies1,2 Majority of children experienced improved health-related quality of…
-
Media Release /Kesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients…
-
Media Release /
Novartis announces FDA and EMA filing acceptances of BEOVU® for patients with diabetic macular edema
Regulatory decisions for BEOVU® (brolucizumab-dbll) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed…
